Aim: To evaluate the expression and prognostic value of the epidermal growth factor receptor HER3 in patients with primary colorectal cancer (CRC) and corresponding lymph node metastases.
Patient And Methods: HER3 expression was analysed immunohistochemically (IHC) in primary tumours and in corresponding lymph node metastases from 236 patients with stage II and III CRC. In 58 primary tumours, fluorescence in situ hybridisation (FISH) detection was performed.
Results: HER3 was detected at high frequency in the cell membrane. Seventy percent of the primary tumours had a high HER3 expression compared to 75% in the lymph node metastases. HER3 expression in the primary tumour was an independent prognostic factor for overall survival in the entire group of patients (p=0.026) and in the subgroup of patients with colon cancer stage II (p=0.030). A high HER3 expression in the primary tumour was associated with worse clinical outcome. The expression of HER3 was homogenous within the primary tumour (r=0.9, p<0.0001) and correlated with the HER3 expression in corresponding lymph node metastases (r=0.6, p<0.0001). No gene amplification with respect to HER3 was seen in primary tumours using FISH analysis.
Conclusion: A high HER3 expression was found in 70% of the primary CRC tumours and in 75% of the corresponding lymph node metastases. HER3 expression in the tumour was an independent prognostic factor, where a high HER3 expression was associated with worse clinical outcome. There was a correlation in HER3 expression between primary tumour and corresponding lymph node metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2013.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dorsal-ventral patterning of neural progenitors in the posterior neural tube, which gives rise to the spinal cord, has served as a model system to understand how extracellular signals organize developing tissues. While previous work has shown that signaling gradients diversify progenitor fates at the dorsal and ventral ends of the tissue, the basis of fate specification in intermediate regions has remained unclear. Here we use zebrafish to investigate the neural plate, which precedes neural tube formation, and show that its pre-patterning by a distinct signaling environment enables intermediate fate specification.
View Article and Find Full Text PDFAntibody-Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives.
Int J Mol Sci
December 2024
Department of Oncology, University Hospital of Udine, 33100 Udine, Italy.
Antibody-drug conjugates (ADCs) represent one of the most promising and rapidly emerging anti-cancer therapies because they combine the cytotoxic effect of the conjugate payload and the high selectivity of the monoclonal antibody, which binds a specific membrane antigen expressed by the tumor cells. In non-small cell lung cancer (NSCLC), ADCs are being investigated targeting human epidermal growth factor receptor 2 (), human epidermal growth factor receptor 3 (), trophoblast cell surface antigen 2 (), Mesenchymal-epithelial transition factor (), and carcinoembryonic antigen-related cell adhesion molecule 5 (). To date, Trastuzumab deruxtecan is the only ADC that has been approved by the FDA for the treatment of patients with NSCLC, but several ongoing studies, both using ADCs as monotherapy and combined with other therapies, are investigating the efficacy of new ADCs.
View Article and Find Full Text PDFERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer.
BMC Genom Data
January 2025
Medical Oncology, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China.
Article Synopsis
- The study investigates the role of ERBB3 expression in HER2-positive breast cancer and its potential impact on treatment resistance.
- Through various bioinformatics techniques and machine learning algorithms, the researchers identified three key genes—PBX1, IGHM, and CXCL13—that are linked to ERBB3 expression and can serve as prognostic markers.
- Findings suggest that these genes may influence breast cancer cell behavior and prognosis, emphasizing their significance in understanding HER2-positive breast cancer treatment outcomes.
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.
Cancer Commun (Lond)
January 2025
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb.
FEBS Open Bio
January 2025
Cell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Article Synopsis
- Pancreatic ductal adenocarcinomas (PDAC) are highly aggressive and lack effective treatments; this study examines potential new therapies using rat monoclonal antibodies (mAbs) targeting specific membrane proteins.
- Key membrane proteins such as HER1-4, MET, S1PR1, LAT1, and CD44v are frequently expressed in PDAC, and targeting them with mAbs demonstrated growth inhibition in various cancer cell lines.
- High levels of CD44v in PDAC correlate with poor patient prognosis, indicating that targeting CD44v and related proteins could provide new diagnostic and therapeutic avenues for treating this aggressive cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!